NKARTA INC. - COMMON

Nkarta to Participate in an Upcoming Investor Conference

26 Nov 2024 06:02:00 By Nasdaq GlobeNewswire

Nkarta to Participate in an Upcoming Investor Conference

12 Nov 2024 07:02:00 By Nasdaq GlobeNewswire

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

07 Nov 2024 15:02:00 By Nasdaq GlobeNewswire

Nkarta to Participate in Upcoming Investor Conference

03 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

13 Aug 2024 20:03:42 By Nasdaq GlobeNewswire

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

13 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

24 Jul 2024 05:00:00 By Nasdaq GlobeNewswire

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

16 Jul 2024 05:01:00 By Nasdaq GlobeNewswire

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

27 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

13 Jun 2024 15:01:00 By Nasdaq GlobeNewswire

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

09 May 2024 15:01:00 By Nasdaq GlobeNewswire

Nkarta to Participate in Upcoming Investor Conferences

03 Apr 2024 15:02:00 By Nasdaq GlobeNewswire

Nkarta Announces Pricing of $240 Million Underwritten Offering

25 Mar 2024 05:30:00 By Nasdaq GlobeNewswire

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

21 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Nkarta to Participate in Upcoming Investor Conferences

28 Feb 2024 07:01:00 By Nasdaq GlobeNewswire

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

09 Dec 2023 19:31:00 By Nasdaq GlobeNewswire

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

09 Nov 2023 15:02:00 By Nasdaq GlobeNewswire

Nkarta to Participate at Upcoming Investor Conferences

07 Nov 2023 07:02:00 By Nasdaq GlobeNewswire

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

17 Oct 2023 06:01:00 By Nasdaq GlobeNewswire

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

16 Oct 2023 15:01:00 By Nasdaq GlobeNewswire